The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Ono’s Colorectal Cancer Med Braftovi Widens Label in South Korea
Ono Pharmaceutical said on January 13 that its South Korean unit has secured an additional approval for the BRAF inhibitor Braftovi (encorafenib) for the frontline treatment of colorectal cancer. The approval, granted by South Korea’s Ministry of Food and Drug…
To read the full story
Related Article
- Ono’s Colorectal Cancer Drug Braftovi Approved in South Korea
August 23, 2021
BUSINESS
- Eisai Picks Up Rights to Nuvation’s Taletrectinib in Europe, Other Regions
January 14, 2026
- Ono’s Colorectal Cancer Med Braftovi Widens Label in South Korea
January 14, 2026
- Nxera Snags US$3.6 Million Early-Stage Milestone on OX2R Agonist
January 14, 2026
- Gla-Alpha Launched in Singapore via Kowa: DWTI
January 14, 2026
- RaQualia Partner Files US NDA for Tegoprazan
January 14, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…